Description
Pumitamig is an investigational medication currently being studied as a potential treatment for colorectal cancer. It is being evaluated in clinical trials, specifically in patients with previously untreated, unresectable, or metastatic colorectal cancer. The trials are comparing pumitamig in combination with chemotherapy to bevacizumab (Avastin) in combination with chemotherapy. Pumitamig is being studied in patients whose tumors have specific characteristics, such as a BRAF mutation (specifically V600E) or are MSI-H (microsatellite instability-high). The goal of these trials is to assess the safety and effectiveness of pumitamig in this setting.
Mechanism of Action
Pumitamig is being investigated for its potential role in treating colorectal cancer. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is being tested in combination with standard chemotherapy regimens to see if it can improve outcomes compared to existing treatments like bevacizumab plus chemotherapy.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.